Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma
The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically with the introduction of targeted therapies including sunitinib, sorafenib, and temsirolimus. Because patients with conventional clear cell histology account for 75- 80% of all patients with RCC, there has been little ac...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-12-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | http://oncologyreviews.org/index.php/or/article/view/152 |
| _version_ | 1797965947688976384 |
|---|---|
| author | Daniel Y.C. Heng Ronald M. Bukowski |
| author_facet | Daniel Y.C. Heng Ronald M. Bukowski |
| author_sort | Daniel Y.C. Heng |
| collection | DOAJ |
| description | The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically with the introduction of targeted therapies including sunitinib, sorafenib, and temsirolimus. Because patients with conventional clear cell histology account for 75- 80% of all patients with RCC, there has been little accumulated evidence on the treatment of patients with non-clear cell histologies. Most clinical trials have excluded them from enrolment, except for randomized studies investigating temsirolimus. Many retrospective studies on the use of all three of these targeted therapies in patients with non-clear cell histology have demonstrated response rates ranging from 3.7%–16%. Although response rates may not be as high compared to patients with clear cell histologies, targeted therapy does provide a clinically meaningful response. |
| first_indexed | 2024-04-11T02:08:01Z |
| format | Article |
| id | doaj.art-063cd8102bc94e95855b323d9d13cd95 |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T02:08:01Z |
| publishDate | 2011-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-063cd8102bc94e95855b323d9d13cd952023-01-03T02:37:59ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652011-12-0113170176146Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinomaDaniel Y.C. Heng0Ronald M. Bukowski1Experimental Therapeutics, Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, ClevelandExperimental Therapeutics, Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, ClevelandThe treatment of metastatic renal cell carcinoma (RCC) has changed dramatically with the introduction of targeted therapies including sunitinib, sorafenib, and temsirolimus. Because patients with conventional clear cell histology account for 75- 80% of all patients with RCC, there has been little accumulated evidence on the treatment of patients with non-clear cell histologies. Most clinical trials have excluded them from enrolment, except for randomized studies investigating temsirolimus. Many retrospective studies on the use of all three of these targeted therapies in patients with non-clear cell histology have demonstrated response rates ranging from 3.7%–16%. Although response rates may not be as high compared to patients with clear cell histologies, targeted therapy does provide a clinically meaningful response.http://oncologyreviews.org/index.php/or/article/view/152Renal cell cancer - Non-clear cell - Papillary - Chromophobe - Collecting duct - Sunitinib - Sorafenib - Temsirolimus |
| spellingShingle | Daniel Y.C. Heng Ronald M. Bukowski Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma Oncology Reviews Renal cell cancer - Non-clear cell - Papillary - Chromophobe - Collecting duct - Sunitinib - Sorafenib - Temsirolimus |
| title | Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma |
| title_full | Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma |
| title_fullStr | Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma |
| title_full_unstemmed | Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma |
| title_short | Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma |
| title_sort | renal cell carcinoma evolving approaches to advanced non clear cell carcinoma |
| topic | Renal cell cancer - Non-clear cell - Papillary - Chromophobe - Collecting duct - Sunitinib - Sorafenib - Temsirolimus |
| url | http://oncologyreviews.org/index.php/or/article/view/152 |
| work_keys_str_mv | AT danielycheng renalcellcarcinomaevolvingapproachestoadvancednonclearcellcarcinoma AT ronaldmbukowski renalcellcarcinomaevolvingapproachestoadvancednonclearcellcarcinoma |